Drug intelligence / Profile preview

V540C

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**V540C** is an investigational prophylactic human papillomavirus vaccine being developed by Merck. It is being evaluated in the Phase 1 V540C-003 study in healthy adults in Belgium for prevention of human papillomavirus infection. Publicly available trial information does not disclose its antigen composition, vaccine platform, valency, adjuvant, dosage form, administration route, or specific HPV types targeted.

Targets

TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on V540C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V540C.

Explore the full profile